Absolutely, and I have posted on this topic a few times before. However, if the ligand is found to always be present or needs to be present in a receptor complex with MMP-2 for binding (as is suspected) then it won't have much practical impact on cancer target selection as you can just continue to select based on MMP-2 expression. One could imagine the possibility of variable affinity based on genetic variants, however, which could add granularity to patient stratification.
CHM Price at posting:
29.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)